Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

X4 Pharmaceuticals (XFOR) Other Gross PP&E Adjustments (2017 - 2025)

X4 Pharmaceuticals filings provide 9 years of Other Gross PP&E Adjustments readings, the most recent being $5000.0 for Q4 2025.

  • On a quarterly basis, Other Gross PP&E Adjustments rose 100.36% to $5000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $5000.0, a 100.36% increase, with the full-year FY2025 number at $5000.0, up 100.36% from a year prior.
  • Other Gross PP&E Adjustments hit $5000.0 in Q4 2025 for X4 Pharmaceuticals, up from -$1.8 million in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of $5000.0 in Q4 2025 to a low of -$7.6 million in Q1 2021.
  • Median Other Gross PP&E Adjustments over the past 5 years was -$3.9 million (2023), compared with a mean of -$4.0 million.
  • Biggest five-year swings in Other Gross PP&E Adjustments: plummeted 737.34% in 2021 and later skyrocketed 100.36% in 2025.
  • X4 Pharmaceuticals' Other Gross PP&E Adjustments stood at -$6.5 million in 2021, then grew by 24.34% to -$4.9 million in 2022, then surged by 32.9% to -$3.3 million in 2023, then skyrocketed by 57.82% to -$1.4 million in 2024, then soared by 100.36% to $5000.0 in 2025.
  • The last three reported values for Other Gross PP&E Adjustments were $5000.0 (Q4 2025), -$1.8 million (Q3 2025), and -$1.2 million (Q2 2025) per Business Quant data.